{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T22:08:23Z","timestamp":1774303703253,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"DOI":"10.1186\/s12866-025-03923-7","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T04:08:40Z","timestamp":1743394120000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of ciprofloxacin and aminoglycoside susceptibility testing for ceftriaxone non-susceptible Enterobacterales by disk diffusion and VITEK 2 vs. broth microdilution using updated Clinical and Laboratory Standards Institute breakpoints"],"prefix":"10.1186","volume":"25","author":[{"given":"Zahra N.","family":"Sohani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Lieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makeda","family":"Semret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew P.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Simic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reggie","family":"Bamba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Lawandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"3923_CR1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S1473-3099(08)70041-0","volume":"8","author":"J Pitout","year":"2008","unstructured":"Pitout J, Laupland K. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159\u201366.","journal-title":"Lancet Infect Dis"},{"key":"3923_CR2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"CJ Murray","year":"2022","unstructured":"Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629\u201355.","journal-title":"Lancet"},{"key":"3923_CR3","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1128\/AAC.44.12.3249-3256.2000","volume":"44","author":"L Kotra","year":"2000","unstructured":"Kotra L, Haddad J, Mobashery S. Perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrob Agents Chemother. 2000;44:3249\u201356.","journal-title":"Antimicrob Agents Chemother"},{"key":"3923_CR4","first-page":"587","volume":"66","author":"P Sharma","year":"2009","unstructured":"Sharma P, Jain A, Jain S. Fluoroquinolone antibacterials: a review on chemistry, microbiology and therapeutic prospects. Acta Pol Pharm. 2009;66:587\u2013604.","journal-title":"Acta Pol Pharm"},{"key":"3923_CR5","doi-asserted-by":"publisher","first-page":"e02072","DOI":"10.1128\/JCM.02072-18","volume":"57","author":"T Van","year":"2019","unstructured":"Van T, Minejima E, Chiu C, Butler-Wu S. Don\u2019t get wound up: revised fluoroquinolone breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol. 2019;57:e02072-e2118.","journal-title":"J Clin Microbiol"},{"key":"3923_CR6","unstructured":"CLSI. Fluoroquinolone breakpoints for enterobacteriaceae and pseudomonas aeruginosa. 1st ed. CLSI rationale document MR02. Wayne, PA: Clinical and Laboratory Standards Institute; 2019"},{"key":"3923_CR7","doi-asserted-by":"publisher","first-page":"e00074","DOI":"10.1128\/AAC.00074-21","volume":"65","author":"HY Huang","year":"2021","unstructured":"Huang HY, Wang CF, Lu PL. Clinical impact of the revised 2019 CLSI levofloxacin breakpoints in patients with Enterobacterals Bacteremia. Antimicrob Agents Chemother. 2021;65:e00074-e121.","journal-title":"Antimicrob Agents Chemother"},{"key":"3923_CR8","doi-asserted-by":"publisher","first-page":"ofad058","DOI":"10.1093\/ofid\/ofad058","volume":"10","author":"H Sader","year":"2023","unstructured":"Sader H, Mendes R, Kimbrough J, Kantro V, Castanheira M. Impact of the recent clinical and laboratory standards institute breakpoint changes on the antimicrobial spectrum of aminoglycosides and the activity of plazomicin against multidrug-resistant and carbapenem-resistant Enterobacterales from United States Medical Centers. Open forum Infect Dis. 2023;10:ofad058.","journal-title":"Open forum Infect Dis."},{"key":"3923_CR9","unstructured":"\u00a0Hirsch E, Bixby M. What's new in 2022 from the CLSI subcommitte on antimicrobial susceptibility testing. Contagion. 2022;7(5):6\u20137.\u00a0"},{"key":"3923_CR10","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Guidance on aminoglycosides: Breakpoints and dosing. Version 1.0. 2020 [cited 2025 Mar 27]. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Guidance_documents\/Aminoglycoside_guidance_document_20200121.pdf.\u00a0"},{"key":"3923_CR11","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; M07-Ed11","author":"CLSI","year":"2018","unstructured":"CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; M07-Ed11. Wayne: Clinical and Laboratory Standards Institute; 2018."},{"key":"3923_CR12","volume-title":"Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard-Twelfth Edition M02-A12","author":"CLSI","year":"2015","unstructured":"CLSI. Performance standards for antimicrobial disk susceptibility tests; approved standard-twelfth edition M02-A12. Wayne: Clinical and Laboratory Standards Institute; 2015."},{"key":"3923_CR13","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 34th ed. CLSI supplement M100. Wayne (PA): CLSI; 2024.\u00a0"},{"key":"3923_CR14","volume-title":"31A Verification and Validation of Procedures in the Clinical Microbiology Laboratory","author":"RB Clark","year":"2009","unstructured":"Clark RB, Lewinski MA, Loeffelholz MJ, Tibbetts RJ. 31A verification and validation of procedures in the clinical microbiology laboratory. Washington DC: Cumitech; 2009."},{"issue":"4","key":"3923_CR15","doi-asserted-by":"publisher","first-page":"115799","DOI":"10.1016\/j.diagmicrobio.2022.115799","volume":"104","author":"H Huang","year":"2022","unstructured":"Huang H, Chang Y, Lu P, Yang T, Wang Y, Chen T, Wu J, Lin S. Correlation of Vitek 2 and Agar dilution for levofloxacin susceptibility testing and clinical outcomes of Enterobacterales bacteremia with 2019 CLSI breakpoints. Diagn Microbiol Infect Dis. 2022;104(4):115799.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"9","key":"3923_CR16","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.cmi.2022.05.021","volume":"28","author":"A Sundsfjord","year":"2022","unstructured":"Sundsfjord A, Giske C. The clinical impact of errors in semiautomated antimicrobial susceptibility testing of multidrug-resistant Enterobacterales causing bloodstream infections. Clin Microbiol Infect. 2022;28(9):1179\u201381.","journal-title":"Clin Microbiol Infect"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-03923-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-025-03923-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-03923-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T15:53:14Z","timestamp":1743436394000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmicrobiol.biomedcentral.com\/articles\/10.1186\/s12866-025-03923-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3923"],"URL":"https:\/\/doi.org\/10.1186\/s12866-025-03923-7","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]},"assertion":[{"value":"4 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research study was conducted retrospectively from laboratory specimens obtained for quality control purposes, consent from individual human participants was waived from ethical approval by the MUHC Institutional Review Board in accordance with Article 5.5 of the Tri-Council Policy Statement (TCPS-2).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}